---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-105000"
form_type: "8-K"
ticker: "BCAB"
cik: "0001826892"
company_name: "BioAtla, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T18:12:23.528814+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioAtla Q2 net loss $18.7M; cash $18.2M; Oz-V 45% ORR in HPV+ OPSCC

## Summary
- Net loss of $18.7M for Q2 2025 vs $21.1M in Q2 2024; R&D expense down to $13.7M.
- Cash and cash equivalents $18.2M as of June 30, 2025, down from $49.0M at Dec 31, 2024.
- BA3182 (EpCAM x CD3 TCE) Phase 1 dose-escalation ongoing; data readout expected 2H 2025.
- Oz-V (CAB-ROR2-ADC) shows 45% ORR (5/11) in 2L+ HPV+ OPSCC; FDA meeting planned in 3Q 2025.
- Company advancing partnering discussions; confident in closing at least one transaction in 2025.

## SEC filing metadata
- accession: 0000950170-25-105000
- form_type: 8-K
- ticker: BCAB
- cik: 0001826892
- company_name: BioAtla, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826892/000095017025105000/0000950170-25-105000-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826892/000095017025105000/bcab-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-105000
- JSON: https://secwatch.observer/filing/0000950170-25-105000.json
- Plain text: https://secwatch.observer/filing/0000950170-25-105000.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.